Skip to main content
2024 AABB Annual Meeting Main banner
Icon Legend
This session is not in your favorites.
This session is in your favorites. Click again to remove it.
Presentation Icons
Live Stream Sessions
Live Stream Sessions
Video

Biotherapies, Cellular Therapies, and Immunotherapies

Oral Abstract - Biotherapy Spotlight

Tuesday, October 22, 2024
8:30 AM - 10:00 AM  
Location: 342
CE: 0 CME (AMA Physician Credit) / 1.5 CE (Non-Physician Credit)

    Program Chair(s)

  • DS

    David Stroncek, MD

    National Institutes of Health
    Bethesda, MD, United States

    Disclosure information not submitted.

    PDF

The Biotherapies Spotlight Session will cover several diverse topics. The use of controlled incremental filtration microfluidics rather than monoclonal antibody selection systems to isolate B-cells from whole blood will be discussed. A comprehensive analysis of the heterogeneity of megakaryocytes produced from umbilical cord CD34+ cells will be presented. The impact of the growth of CAR T-cell therapies over the past 10 years on the field of cellular therapies will be reviewed. Two novel biotherapies will be discussed. Autoantibodies directed to coagulation factor VIII which inhibit its function is problematic for many patients with hemophilia A. One novel biotherapy involves the use of genetically engineered T-cells to eliminate B-cells producing antibodies to coagulation factor VIII. Another novel biotherapy makes use of a small molecule to increase gamma-globin production by red blood cells from patients with sickle cell disease.

CABP CE Eligible

Learning Objectives:

  • Controlled incremental filtration microfluidics can be used to isolate B-cells from whole blood.
  • CAR T-cells have had a significant impact on cell processing laboratories.
  • Genetically engineered T-cells are being used to eliminate B-cells producing antibodies to coagulation factor VIII in patients with hemophilia A.
  • Megakaryocytes produced from umbilical cord CD34+ cells are heterogenous.
  • Small molecules can be used to increase gamma globin production by red blood cells from patients with sickle cell disease.

Presentations:

  • 8:30 AM - 10:00 AM  
    A Novel Small Molecule Drug-Based Approach for Treating Beta-Globinopathies

    Presenting Author: Jun Liu, MD PhD (she/her/hers) – Mass General Brigham

  • 8:30 AM - 10:00 AM  
    Developing An Engineered T Cell Therapy To Eliminate Inhibitors In Hemophilia A

    Presenting Author: Morgan Hresko, BS, MS – Department of Pathology & Laboratory Medicine, University of Pennsylvania Perelman School of Medicine

  • 8:30 AM - 10:00 AM  
    Generation and Characterization of Megakaryocytes that Producing Platelets Derived from Cord Blood

    Presenting Author: Y M He, MD (she/her/hers) – Blood Center of Zhejiang Province

  • 8:30 AM - 10:00 AM  
    Rapid Isolation of CD4+ T Cells Using a Functionally Closed Microfluidic System for Generating Induced Regulatory T Cells for Adoptive Therapy

    Presenting Author: Sergey S. Shevkoplyas, PhD – University of Houston